FATTY LIVER DISEASE: A COMPREHENSIVE MEDICAL GUIDE

 

(Note: For PDF File Swipe To The End Of Article)

1. INTRODUCTION

Fatty liver disease is one of the most common liver disorders worldwide. It is a condition characterized by excessive accumulation of fat, particularly triglycerides, inside liver cells known as hepatocytes. Under normal physiological conditions, the liver contains a small amount of fat. However, when fat accumulation becomes excessive, it may interfere with normal liver function and contribute to inflammation, cellular injury and progressive scarring.

The medical term for fatty liver is hepatic steatosis. It may occur due to several different causes, including obesity, insulin resistance, type 2 diabetes mellitus, excessive alcohol consumption, metabolic abnormalities, certain medications and some nutritional disorders.

Fatty liver disease is particularly important because many affected individuals do not experience noticeable symptoms during its early stages. A person may have substantial fat accumulation in the liver without experiencing abdominal pain, jaundice or other obvious signs of liver disease.

Although simple fatty liver may remain stable for many years, some individuals develop inflammation and progressive liver damage. In advanced cases, this may result in fibrosis, cirrhosis, liver failure and hepatocellular carcinoma.

The condition was traditionally divided into alcoholic fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Modern medical terminology increasingly uses the term metabolic dysfunction-associated steatotic liver disease (MASLD) for fatty liver associated with cardiometabolic risk factors. Its inflammatory form is called metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH.

Understanding fatty liver disease is essential because early identification, lifestyle modification and appropriate medical management can significantly reduce the risk of disease progression.

---

2. DEFINITION OF FATTY LIVER DISEASE

Fatty liver disease is defined as an abnormal accumulation of lipids, mainly triglycerides, within hepatocytes.

In conventional histological terminology, hepatic steatosis is generally identified when fat is present in at least 5% of hepatocytes.

In simple language, fatty liver means that more fat than normal has accumulated inside the liver cells.

The liver normally performs several important functions, including:

• Metabolism of carbohydrates, proteins and fats.
• Production of bile.
• Detoxification of harmful substances.
• Storage of vitamins and minerals.
• Regulation of blood glucose.
• Synthesis of important plasma proteins.
• Metabolism of medications and hormones.

Excessive fat accumulation can disturb these processes, especially when inflammation and fibrosis develop.

Important terminology:

• Hepatic steatosis: Fat accumulation inside liver cells.
• Steatohepatitis: Fat accumulation accompanied by inflammation and hepatocellular injury.
• Fibrosis: Formation of excessive scar tissue in the liver.
• Cirrhosis: Advanced, widespread scarring that alters liver architecture.
• MASLD: Metabolic dysfunction-associated steatotic liver disease.
• MASH: Metabolic dysfunction-associated steatohepatitis.

---

3. ANATOMY AND NORMAL PHYSIOLOGY OF THE LIVER

To understand fatty liver disease, it is important to understand the normal structure and functions of the liver.

The liver is the largest internal solid organ in the human body. It is situated mainly in the right upper quadrant of the abdomen, immediately below the diaphragm.

It weighs approximately 1.2–1.8 kg in an average adult, although its size varies according to body composition and other factors.

The liver is divided anatomically into right and left lobes, with additional smaller anatomical divisions.

3.1 Microscopic Structure

The basic functional unit of the liver is the hepatic lobule.

A typical hepatic lobule contains:

• Hepatocytes.
• Sinusoids.
• Kupffer cells.
• Bile canaliculi.
• Central veins.
• Portal triads.

Hepatocytes

Hepatocytes are the main functional cells of the liver. They perform metabolic activities, produce bile, synthesize proteins and process nutrients.

These cells are particularly important in fatty liver disease because triglycerides accumulate inside them.

Kupffer Cells

Kupffer cells are specialized macrophages located within hepatic sinusoids.

Their main functions include:

• Removal of bacteria.
• Destruction of damaged cells.
• Phagocytosis of cellular debris.
• Participation in inflammatory responses.

During fatty liver inflammation, Kupffer cells may become activated and release inflammatory mediators.

Hepatic Sinusoids

Sinusoids are specialized vascular channels through which blood flows between hepatocytes.

They receive blood from the portal vein and hepatic artery.

Bile Canaliculi

These small channels collect bile produced by hepatocytes and transport it toward the bile ducts.

3.2 Blood Supply of the Liver

The liver has a dual blood supply:

1. Portal vein: Provides approximately 75% of hepatic blood flow and carries nutrient-rich blood from the gastrointestinal tract.
2. Hepatic artery: Supplies oxygenated blood to the liver.

Blood eventually drains through the hepatic veins into the inferior vena cava.

3.3 Normal Fat Metabolism

The liver plays a central role in lipid metabolism.

It receives fatty acids from adipose tissue, dietary sources and newly synthesized fatty acids.

These fatty acids may undergo several processes:

• Oxidation to produce energy.
• Conversion into triglycerides.
• Storage in small quantities.
• Packaging into very-low-density lipoproteins (VLDL).
• Transport to other tissues.

Fatty liver develops when fat accumulation exceeds the liver's ability to oxidize fatty acids or export triglycerides.

---

4. CLASSIFICATION OF FATTY LIVER DISEASE

Fatty liver disease can be classified according to its underlying cause.

4.1 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

MASLD is characterized by hepatic steatosis accompanied by at least one cardiometabolic risk factor, without harmful alcohol consumption being the principal explanation.

Important associated conditions include:

• Obesity.
• Abdominal obesity.
• Type 2 diabetes mellitus.
• Hypertension.
• Hypertriglyceridemia.
• Low HDL cholesterol.
• Other manifestations of metabolic dysfunction.

MASLD is strongly associated with insulin resistance and metabolic syndrome.

4.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH is an inflammatory form of MASLD.

It is characterized by:

• Hepatic steatosis.
• Lobular inflammation.
• Hepatocellular ballooning injury.

MASH is clinically important because it carries a greater risk of progressive fibrosis than simple steatosis.

Some individuals with MASH develop advanced fibrosis and eventually cirrhosis.

4.3 Alcohol-Associated Liver Disease

Alcohol-associated liver disease develops due to excessive alcohol consumption.

Alcohol is metabolized mainly in the liver and produces substances that can cause oxidative stress, mitochondrial dysfunction and hepatocellular injury.

The disease may progress through several stages:

• Alcohol-associated fatty liver.
• Alcohol-associated steatohepatitis.
• Alcohol-associated fibrosis.
• Alcohol-associated cirrhosis.

The amount and duration of alcohol consumption, individual susceptibility, nutritional status and other metabolic risk factors influence disease severity.

4.4 Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD)

MetALD describes individuals who have metabolic dysfunction-associated steatotic liver disease and alcohol consumption above the threshold used for MASLD but below the higher thresholds generally used to classify alcohol-related liver disease.

Metabolic and alcohol-related factors may act together to increase liver injury.

4.5 Other Causes of Hepatic Steatosis

Fat accumulation in the liver may also occur due to:

• Certain medications.
• Rapid weight loss.
• Severe malnutrition.
• Total parenteral nutrition.
• Some inherited metabolic disorders.
• Lipodystrophy.
• Certain endocrine disorders.
• Hepatitis C infection, particularly specific genotypes.
• Wilson disease.
• Other uncommon metabolic conditions.

Identifying the underlying cause is important because management differs according to the type of fatty liver disease.

---

5. EPIDEMIOLOGY AND PREVALENCE

Fatty liver disease is a major global health problem.

MASLD is now recognized as one of the most common causes of chronic liver disease worldwide.

Its prevalence has increased alongside rising rates of:

• Obesity.
• Type 2 diabetes mellitus.
• Sedentary lifestyles.
• Unhealthy dietary habits.
• Metabolic syndrome.
• Insulin resistance.

The disease affects adults of different ages and may also occur in children and adolescents.

5.1 High-Risk Populations

Certain populations have a particularly high risk of developing fatty liver disease.

These include:

• Individuals with obesity.
• Patients with type 2 diabetes.
• People with metabolic syndrome.
• Individuals with elevated triglycerides.
• Patients with hypertension.
• Individuals with abdominal obesity.
• People with a sedentary lifestyle.
• Patients with a family history of metabolic liver disease.

5.2 Age and Gender

Fatty liver can occur at any age.

However, its prevalence generally increases with age, particularly in individuals who develop diabetes, obesity and other metabolic abnormalities.

Both men and women may develop the condition.

Hormonal factors, body fat distribution, alcohol exposure and metabolic characteristics may influence individual risk.

5.3 Importance of Early Detection

The majority of people with simple hepatic steatosis do not immediately develop severe liver disease.

However, identifying individuals with progressive fibrosis is extremely important.

Advanced fibrosis is a stronger predictor of liver-related complications and mortality than the amount of liver fat alone.

---

6. ETIOLOGY AND CAUSES OF FATTY LIVER

Fatty liver disease has multiple causes. In many patients, several risk factors are present simultaneously.

6.1 Obesity

Obesity is one of the most important risk factors for MASLD.

Excess adipose tissue increases the release of free fatty acids into the bloodstream.

These fatty acids are transported to the liver, where they may accumulate as triglycerides.

Obesity is also associated with insulin resistance, chronic low-grade inflammation and altered adipokine production.

Abdominal obesity is particularly important because visceral fat is metabolically active and contributes to insulin resistance.

6.2 Type 2 Diabetes Mellitus

Type 2 diabetes is strongly associated with fatty liver disease.

Insulin resistance increases hepatic glucose production and stimulates pathways involved in fatty acid synthesis.

Patients with type 2 diabetes may have a higher risk of developing MASH, advanced fibrosis and cirrhosis.

Therefore, individuals with type 2 diabetes should receive appropriate assessment for metabolic liver disease and fibrosis risk.

6.3 Insulin Resistance

Insulin resistance is one of the central mechanisms involved in MASLD.

Normally, insulin helps regulate blood glucose and fat metabolism.

When tissues become resistant to insulin:

• Glucose uptake decreases in skeletal muscle.
• Hepatic glucose production may remain elevated.
• Adipose tissue releases more free fatty acids.
• Hepatic triglyceride synthesis increases.
• Liver fat accumulation becomes more likely.

Insulin resistance therefore plays a major role in the development and progression of metabolic fatty liver disease.

6.4 Hyperlipidemia

Hyperlipidemia refers to abnormal levels of lipids in the bloodstream.

Important abnormalities include:

• Increased triglycerides.
• Increased LDL cholesterol.
• Reduced HDL cholesterol.

High circulating fatty acid levels may increase hepatic fat accumulation.

6.5 Metabolic Syndrome

Metabolic syndrome is a combination of metabolic abnormalities that increase the risk of cardiovascular disease and type 2 diabetes.

Its components commonly include:

• Abdominal obesity.
• Elevated blood pressure.
• Increased triglycerides.
• Reduced HDL cholesterol.
• Elevated fasting glucose.

Individuals with metabolic syndrome have a substantially increased risk of MASLD.

6.6 Excessive Alcohol Consumption

Alcohol contributes to hepatic fat accumulation through several mechanisms.

Its metabolism increases the NADH/NAD+ ratio and interferes with normal fatty acid oxidation.

Alcohol may also increase oxidative stress and promote inflammation.

Long-term excessive alcohol consumption can cause progressive liver injury.

6.7 Unhealthy Diet

Dietary habits play an important role in the development of fatty liver.

Risk-associated dietary patterns include:

• Excessive calorie intake.
• Frequent consumption of sugary drinks.
• High intake of refined carbohydrates.
• Excessive saturated fat consumption.
• Frequent consumption of ultra-processed foods.
• Large portions of energy-dense meals.

High consumption of fructose-containing beverages may also contribute to increased hepatic fat production.

6.8 Physical Inactivity

A sedentary lifestyle contributes to obesity, insulin resistance and metabolic abnormalities.

Lack of physical activity reduces energy expenditure and may worsen fat accumulation in the liver.

6.9 Rapid Weight Loss and Malnutrition

Although obesity is a major risk factor, fatty liver may also develop in individuals with severe malnutrition.

Rapid weight loss and prolonged starvation can alter fatty acid metabolism and hepatic lipid transport.

6.10 Medications

Some medications may cause or contribute to hepatic steatosis.

Examples include:

• Amiodarone.
• Tamoxifen.
• Methotrexate.
• Corticosteroids.
• Certain chemotherapy agents.
• Some antiretroviral medications.
• Valproic acid.

The risk varies according to the drug, dose, duration of treatment and individual susceptibility.

Patients should not discontinue prescribed medications without consulting their healthcare professional.

---

7. PATHOPHYSIOLOGY OF FATTY LIVER DISEASE

The pathophysiology of fatty liver disease involves complex interactions between lipid metabolism, insulin resistance, inflammation, oxidative stress and genetic susceptibility.

The development of MASLD is not explained by a single mechanism.

7.1 Increased Delivery of Free Fatty Acids

Adipose tissue normally stores triglycerides.

During insulin resistance, insulin becomes less effective at suppressing lipolysis.

Consequently, more triglycerides are broken down into free fatty acids.

These fatty acids enter the bloodstream and are transported to the liver.

The liver takes up these fatty acids, contributing to hepatic fat accumulation.

7.2 Increased De Novo Lipogenesis

De novo lipogenesis refers to the production of new fatty acids from non-lipid substances, particularly carbohydrates.

Excessive intake of calories, refined carbohydrates and sugar-sweetened beverages may stimulate hepatic fatty acid synthesis.

These newly synthesized fatty acids can be converted into triglycerides.

7.3 Reduced Fatty Acid Oxidation

The liver normally breaks down fatty acids through mitochondrial beta-oxidation.

When fatty acid delivery and synthesis exceed the liver's oxidative capacity, excess lipids accumulate.

Mitochondrial dysfunction may further contribute to this process.

7.4 Increased Triglyceride Storage

Excess fatty acids are converted into triglycerides.

These triglycerides accumulate within intracellular lipid droplets in hepatocytes.

This results in hepatic steatosis.

7.5 Lipotoxicity

Not all accumulated lipids have the same biological effects.

Certain lipid intermediates, including diacylglycerols and ceramides, may produce cellular toxicity.

This process is known as lipotoxicity.

It can interfere with insulin signaling, damage mitochondria and promote inflammatory responses.

7.6 Oxidative Stress

Oxidative stress occurs when the production of reactive oxygen species exceeds the body's antioxidant defense mechanisms.

Excessive fatty acid metabolism and mitochondrial dysfunction may increase reactive oxygen species.

These substances can damage:

• Cellular membranes.
• Proteins.
• Mitochondrial structures.
• DNA.
• Other intracellular components.

Oxidative stress contributes to hepatocellular injury.

7.7 Inflammatory Response

Damaged hepatocytes release signals that activate immune cells.

Kupffer cells and other inflammatory cells produce cytokines and chemokines.

Important inflammatory mediators include:

• Tumor necrosis factor-alpha.
• Interleukin-6.
• Interleukin-1 beta.
• Other inflammatory signaling molecules.

These substances contribute to hepatocellular inflammation and tissue injury.

7.8 Activation of Hepatic Stellate Cells

Hepatic stellate cells are normally involved in vitamin A storage and maintenance of liver tissue.

During chronic inflammation, these cells become activated.

Activated stellate cells produce collagen and other extracellular matrix components.

Excessive collagen deposition leads to hepatic fibrosis.

7.9 Development of Cirrhosis

If chronic liver injury continues, fibrosis may progressively increase.

Eventually, normal liver architecture becomes distorted.

Regenerative nodules and extensive fibrous tissue develop.

This advanced stage is known as cirrhosis.

Cirrhosis can cause portal hypertension, impaired liver function, ascites, variceal bleeding and hepatic encephalopathy.

Simplified sequence of disease progression:

Excess calorie intake and metabolic dysfunction → Insulin resistance → Increased free fatty acid delivery → Hepatic triglyceride accumulation → Steatosis → Inflammation and cellular injury → Fibrosis → Cirrhosis.

Not every patient progresses through all these stages.

---

8. STAGES OF FATTY LIVER DISEASE

Fatty liver disease may be described according to the degree of fat accumulation and the presence of inflammation and fibrosis.

Stage 1: Simple Hepatic Steatosis

This is the earliest stage.

Fat accumulates inside hepatocytes without significant evidence of steatohepatitis.

Characteristics include:

• Increased hepatic fat.
• Usually no significant inflammation.
• No established progressive fibrosis in uncomplicated simple steatosis.
• Frequently no symptoms.
• Often discovered incidentally.

Many individuals remain stable, while others may develop progressive disease.

Stage 2: Steatohepatitis

At this stage, fat accumulation is accompanied by inflammation and hepatocellular injury.

In MASH, characteristic histological findings include:

• Steatosis.
• Lobular inflammation.
• Hepatocyte ballooning.

Patients may continue to have no symptoms.

However, the risk of fibrosis progression is greater.

Stage 3: Hepatic Fibrosis

Chronic inflammation and cellular injury activate hepatic stellate cells.

Collagen begins accumulating within liver tissue.

Fibrosis is commonly graded from F0 to F4:

• F0: No fibrosis.
• F1: Mild fibrosis.
• F2: Moderate fibrosis.
• F3: Advanced fibrosis.
• F4: Cirrhosis.

Stage 4: Cirrhosis

Cirrhosis represents advanced, widespread fibrosis with distortion of the normal hepatic architecture.

Complications may include:

• Portal hypertension.
• Ascites.
• Esophageal varices.
• Splenomegaly.
• Hepatic encephalopathy.
• Jaundice.
• Liver failure.
• Hepatocellular carcinoma.

Some patients with cirrhosis remain compensated for years, while others develop decompensation.

---

9. CLINICAL FEATURES OF FATTY LIVER DISEASE

Clinical manifestations depend on the severity of liver disease.

Many patients with early-stage fatty liver remain asymptomatic.

9.1 Asymptomatic Presentation

The majority of patients with uncomplicated hepatic steatosis do not experience specific symptoms.

The condition may be discovered during:

• Routine health examinations.
• Abdominal ultrasonography.
• Investigation of elevated liver enzymes.
• Assessment of diabetes or obesity.
• Evaluation of abdominal discomfort.

9.2 Fatigue

Fatigue is one of the commonly reported symptoms.

Patients may describe:

• Persistent tiredness.
• Reduced energy.
• Difficulty maintaining normal daily activities.
• Generalized weakness.

However, fatigue is nonspecific and may be related to several other medical conditions.

9.3 Right Upper Quadrant Discomfort

Some patients experience discomfort in the right upper quadrant of the abdomen.

This may be associated with enlargement of the liver and stretching of its capsule.

The discomfort is usually described as:

• Dull pain.
• Mild aching.
• Fullness beneath the right ribs.
• Occasional abdominal heaviness.

Severe abdominal pain should prompt evaluation for other causes.

9.4 Hepatomegaly

Hepatomegaly means enlargement of the liver.

It may occur due to excessive fat accumulation and associated inflammation.

On physical examination, the liver may be palpable below the right costal margin.

However, a normal examination does not exclude fatty liver.

9.5 Abdominal Obesity

Many patients have increased abdominal fat.

This is particularly common in metabolic fatty liver disease.

9.6 Features of Associated Metabolic Disorders

Patients may also have manifestations of associated conditions, including:

• Increased body weight.
• Hypertension.
• Type 2 diabetes.
• Hypertriglyceridemia.
• Acanthosis nigricans.
• Central obesity.

9.7 Features of Advanced Liver Disease

When advanced fibrosis or cirrhosis develops, additional manifestations may appear.

These include:

• Jaundice.
• Ascites.
• Peripheral edema.
• Easy bruising.
• Muscle wasting.
• Splenomegaly.
• Spider angiomas.
• Palmar erythema.
• Gastrointestinal bleeding.
• Confusion and altered consciousness.

These findings require prompt medical assessment.

---

10. COMPLICATIONS OF FATTY LIVER DISEASE

Fatty liver disease may lead to several hepatic and extrahepatic complications.

10.1 Steatohepatitis

Progressive inflammation may cause hepatocellular damage.

This is an important stage in the development of chronic liver injury.

10.2 Hepatic Fibrosis

Persistent inflammation stimulates collagen deposition.

Fibrosis may gradually progress over many years.

10.3 Cirrhosis

Advanced fibrosis can lead to cirrhosis.

The liver becomes nodular, firm and structurally distorted.

Its ability to perform essential functions may become impaired.

10.4 Portal Hypertension

Portal hypertension develops when resistance to blood flow through the liver increases.

It may cause:

• Esophageal varices.
• Gastric varices.
• Ascites.
• Splenomegaly.
• Portosystemic collateral circulation.

10.5 Ascites

Ascites refers to abnormal accumulation of fluid within the peritoneal cavity.

It commonly develops in decompensated cirrhosis due to portal hypertension and changes in renal sodium and water handling.

Clinical features include:

• Abdominal distension.
• Increased abdominal girth.
• Weight gain.
• Shifting dullness.
• Fluid thrill in large-volume ascites.

10.6 Esophageal Varices

Increased portal pressure causes the development of dilated collateral veins, particularly in the esophagus.

These veins may rupture and cause severe gastrointestinal bleeding.

Manifestations include:

• Hematemesis.
• Melena.
• Dizziness.
• Hypotension.
• Hemorrhagic shock.

Variceal bleeding is a medical emergency.

10.7 Hepatic Encephalopathy

Hepatic encephalopathy is a neuropsychiatric complication of advanced liver disease.

It occurs due to impaired hepatic detoxification and altered communication between the liver, gut and brain.

Clinical manifestations include:

• Sleep disturbances.
• Personality changes.
• Confusion.
• Disorientation.
• Asterixis.
• Reduced consciousness.
• Coma.

10.8 Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common primary malignancy of the liver.

It may develop in patients with MASH-related cirrhosis.

In some individuals, HCC may also occur without established cirrhosis.

10.9 Cardiovascular Disease

Cardiovascular disease is a major cause of morbidity and mortality among individuals with MASLD.

Associated conditions include:

• Coronary artery disease.
• Myocardial infarction.
• Stroke.
• Heart failure.
• Peripheral vascular disease.

This is why treatment should address overall metabolic health rather than focusing exclusively on liver fat.

10.10 Chronic Kidney Disease

MASLD is associated with an increased risk of chronic kidney disease.

The relationship is influenced by shared metabolic risk factors such as diabetes, hypertension and obesity.

---

11. DIAGNOSIS OF FATTY LIVER DISEASE

Diagnosis involves identifying hepatic steatosis, assessing possible causes and determining whether significant fibrosis is present.

A combination of clinical assessment, laboratory investigations and imaging techniques is used.

11.1 Medical History

A detailed history should include:

• Duration of symptoms.
• Alcohol consumption.
• Dietary habits.
• Physical activity.
• Weight changes.
• History of diabetes.
• History of hypertension.
• History of dyslipidemia.
• Family history of liver disease.
• Current medications.
• Previous liver investigations.

Alcohol history should be assessed carefully because alcohol and metabolic factors may coexist.

11.2 Physical Examination

The examination should assess:

• Body mass index.
• Waist circumference.
• Blood pressure.
• Signs of insulin resistance.
• Hepatomegaly.
• Splenomegaly.
• Jaundice.
• Ascites.
• Peripheral edema.
• Signs of chronic liver disease.

A normal physical examination does not rule out fatty liver.

---

12. LABORATORY INVESTIGATIONS

Several laboratory tests are useful in the assessment of fatty liver disease.

12.1 Liver Function Tests

Liver blood tests may include:

• Alanine aminotransferase (ALT).
• Aspartate aminotransferase (AST).
• Alkaline phosphatase (ALP).
• Gamma-glutamyl transferase (GGT).
• Total bilirubin.
• Direct bilirubin.
• Albumin.
• Prothrombin time and INR.

ALT and AST are markers of hepatocellular injury rather than direct measurements of liver function.

Alanine Aminotransferase

ALT is an enzyme found predominantly in hepatocytes.

It may increase when hepatocytes are damaged.

Mild ALT elevation is commonly observed in MASLD.

However, normal ALT does not exclude MASH or advanced fibrosis.

Aspartate Aminotransferase

AST is found in the liver as well as skeletal muscle, heart and other tissues.

It may increase due to liver injury or non-hepatic conditions.

In advanced fibrosis and cirrhosis, AST may become higher than ALT.

Alkaline Phosphatase

ALP is present in several tissues, including the liver and bones.

It may increase in cholestatic liver disorders.

A mild elevation may occur in some patients with fatty liver.

Gamma-Glutamyl Transferase

GGT is a liver-associated enzyme that may increase in metabolic liver disease, alcohol exposure and cholestatic conditions.

It is not specific for fatty liver.

Bilirubin

Bilirubin is produced during the breakdown of heme.

It is normally processed by the liver and excreted through bile.

Bilirubin is usually normal in uncomplicated fatty liver.

In advanced liver disease, bilirubin may increase.

Serum Albumin

Albumin is synthesized by the liver.

Reduced albumin may indicate impaired synthetic function, although other conditions such as kidney disease and malnutrition can also cause low albumin.

Prothrombin Time and INR

The liver produces several clotting factors.

Advanced liver dysfunction may result in prolonged prothrombin time and increased INR.

12.2 Fasting Blood Glucose

This test helps identify impaired glucose regulation and diabetes.

12.3 HbA1c

HbA1c estimates average blood glucose over approximately three months.

It is useful for diagnosing and monitoring diabetes.

12.4 Lipid Profile

A lipid profile usually includes:

• Total cholesterol.
• LDL cholesterol.
• HDL cholesterol.
• Triglycerides.

It helps identify associated dyslipidemia.

12.5 Complete Blood Count

A complete blood count may help identify anemia, thrombocytopenia and other abnormalities.

Low platelet counts may be an indirect clue to advanced fibrosis or portal hypertension, although many other conditions can cause thrombocytopenia.

12.6 Renal Function Tests

These may include:

• Serum creatinine.
• Blood urea nitrogen.
• Estimated glomerular filtration rate.
• Electrolytes.

They are useful because metabolic fatty liver disease is associated with kidney disease.

12.7 Additional Investigations

Depending on the clinical situation, clinicians may request:

• Hepatitis B surface antigen.
• Hepatitis C antibody.
• Iron studies.
• Ferritin.
• Transferrin saturation.
• Autoimmune liver disease markers.
• Ceruloplasmin.
• Alpha-1 antitrypsin testing.
• Thyroid function tests.

These investigations help exclude other causes of liver abnormalities.

---

13. IMAGING STUDIES

Imaging plays an important role in detecting hepatic steatosis and evaluating liver fibrosis.

13.1 Abdominal Ultrasonography

Ultrasonography is commonly used as an initial imaging investigation.

Typical findings include:

• Increased hepatic echogenicity.
• Bright liver appearance.
• Increased liver-to-kidney echogenicity.
• Reduced visualization of intrahepatic vessels.
• Reduced visualization of the diaphragm in more severe steatosis.

Ultrasound is widely available and relatively inexpensive.

However, it has limitations.

It may fail to detect mild steatosis and cannot reliably distinguish simple steatosis from MASH.

It is also not sufficiently accurate to exclude advanced fibrosis.

13.2 FibroScan

FibroScan is a non-invasive method used to assess liver stiffness and estimate hepatic fat.

It uses transient elastography.

Two important measurements are:

Liver stiffness measurement (LSM)

This estimates liver stiffness and helps assess fibrosis risk.

Controlled attenuation parameter (CAP)

This estimates hepatic fat accumulation.

FibroScan is useful for identifying individuals who may require specialist evaluation.

Results must be interpreted according to clinical context and technical limitations.

13.3 Computed Tomography

CT scanning may identify hepatic steatosis through changes in liver attenuation.

It may demonstrate reduced liver density compared with the spleen.

However, CT involves radiation exposure and is not generally the preferred method for routine screening of fatty liver.

13.4 Magnetic Resonance Imaging

MRI provides detailed information about liver fat.

MRI proton density fat fraction (MRI-PDFF) is a highly useful quantitative method for measuring hepatic fat.

It can detect relatively small changes in liver fat content.

13.5 Magnetic Resonance Elastography

Magnetic resonance elastography evaluates liver stiffness using MRI-based techniques.

It is useful in assessing fibrosis, particularly when conventional non-invasive tests are inconclusive.

13.6 Liver Biopsy

Liver biopsy involves obtaining a small sample of liver tissue for microscopic examination.

It can identify:

• Steatosis.
• Hepatocellular ballooning.
• Lobular inflammation.
• Fibrosis.
• Other underlying liver disorders.

Biopsy is considered the reference standard for histological diagnosis of MASH.

However, it is invasive and carries risks such as bleeding and pain.

It is not required for every patient.

It may be considered when:

• The diagnosis remains uncertain.
• Other liver diseases are suspected.
• Non-invasive tests are inconclusive.
• Histological staging would influence treatment decisions.

---

14. NON-INVASIVE FIBROSIS ASSESSMENT

One of the most important aspects of modern fatty liver management is identifying patients with significant fibrosis.

Liver enzyme levels alone cannot reliably determine fibrosis severity.

14.1 FIB-4 Index

FIB-4 is a commonly used blood-based fibrosis risk assessment tool.

It uses:

• Age.
• AST.
• ALT.
• Platelet count.

The formula is:

FIB-4 = (Age × AST) / (Platelet count × √ALT)

Age is measured in years, AST and ALT in U/L, and platelets in 10⁹/L.

In many adults, a FIB-4 value below 1.3 is used as a low-risk threshold for advanced fibrosis.

A value of 1.3 or higher generally prompts further assessment, such as elastography or another fibrosis test.

In adults older than 65 years, a higher lower-risk threshold of 2.0 is commonly used.

FIB-4 has limitations, particularly in younger adults and during acute illness.

It is a risk assessment tool, not a definitive diagnosis.

14.2 Sequential Assessment

A commonly recommended approach involves:

1. Initial assessment using FIB-4.
2. Secondary assessment using transient elastography or another validated test when indicated.
3. Specialist referral when advanced fibrosis is suspected.

This approach helps reduce unnecessary invasive investigations while identifying high-risk individuals.

---

15. DIFFERENTIAL DIAGNOSIS

Not every patient with increased liver enzymes or a bright liver on ultrasound has MASLD.

Other conditions must be considered.

Important differential diagnoses include:

15.1 Alcohol-Associated Liver Disease

A history of excessive alcohol consumption may indicate alcohol-associated steatosis or steatohepatitis.

15.2 Viral Hepatitis

Hepatitis B and hepatitis C may cause chronic liver inflammation and elevated liver enzymes.

15.3 Autoimmune Hepatitis

This is an immune-mediated condition in which the immune system attacks liver tissue.

15.4 Hemochromatosis

Hemochromatosis is associated with excessive iron accumulation in body tissues, including the liver.

15.5 Wilson Disease

Wilson disease is an inherited disorder of copper metabolism.

Copper accumulation may damage the liver and nervous system.

15.6 Drug-Induced Liver Injury

Certain medications can cause hepatic steatosis, inflammation or other forms of liver injury.

15.7 Alpha-1 Antitrypsin Deficiency

This inherited disorder may cause liver disease due to abnormal accumulation of alpha-1 antitrypsin protein.

Accurate diagnosis is important because treatment differs according to the underlying condition.

---

16. MANAGEMENT OF FATTY LIVER DISEASE

The management of fatty liver depends on its underlying cause, disease stage and associated metabolic conditions.

The main objectives are:

• Reduce excessive hepatic fat.
• Improve insulin sensitivity.
• Prevent inflammation and fibrosis progression.
• Treat associated metabolic disorders.
• Reduce cardiovascular risk.
• Prevent cirrhosis and its complications.
• Improve long-term health and quality of life.

Lifestyle modification remains the foundation of management for most patients with MASLD.

---

17. WEIGHT REDUCTION

Weight management is one of the most effective interventions for patients with MASLD who have overweight or obesity.

Excess body fat contributes to insulin resistance and increased delivery of free fatty acids to the liver.

Reducing body weight can improve hepatic steatosis and inflammation.

17.1 Recommended Weight Reduction

The amount of weight loss influences the degree of liver improvement.

Commonly used targets include:

• At least 5% sustained weight reduction to reduce liver fat.
• Approximately 7–10% to improve steatohepatitis.
• At least 10% to provide a greater chance of fibrosis improvement.

These are clinical targets rather than guaranteed outcomes.

Not every patient will experience the same degree of improvement.

17.2 Importance of Gradual Weight Loss

Weight loss should be gradual and sustainable.

Crash diets and extreme fasting are not recommended.

Rapid weight loss may cause nutritional deficiencies and other complications.

A structured plan involving dietary changes and physical activity is preferable.

17.3 Maintaining Weight Reduction

Long-term maintenance is essential.

Patients should develop sustainable habits rather than following temporary diets.

Regular monitoring of body weight and waist circumference can help assess progress.

---

18. DIETARY MANAGEMENT

Diet plays an essential role in the treatment and prevention of fatty liver disease.

The goal is to improve overall nutritional quality and reduce excessive calorie intake.

18.1 Mediterranean-Style Diet

A Mediterranean-style dietary pattern is commonly recommended.

It emphasizes:

• Vegetables.
• Fruits.
• Whole grains.
• Legumes.
• Nuts.
• Seeds.
• Fish.
• Olive oil.
• Other sources of unsaturated fats.

This dietary pattern may improve metabolic health and reduce hepatic fat.

18.2 Foods to Prefer

Vegetables

Vegetables provide fiber, vitamins, minerals and antioxidants.

Examples include:

• Spinach.
• Broccoli.
• Carrots.
• Cauliflower.
• Cucumbers.
• Tomatoes.
• Green beans.
• Leafy vegetables.

Fruits

Whole fruits provide fiber and essential micronutrients.

Examples include:

• Apples.
• Oranges.
• Guava.
• Berries.
• Pears.
• Papaya.

Whole fruit is generally preferable to fruit juice because it contains more fiber and is less concentrated in rapidly consumed sugars.

Whole Grains

Examples include:

• Oats.
• Whole-wheat bread.
• Brown rice.
• Barley.
• Whole-grain cereals.

Whole grains may improve satiety and help regulate blood glucose.

Protein Sources

Healthy protein sources include:

• Fish.
• Skinless chicken.
• Eggs.
• Lentils.
• Beans.
• Chickpeas.
• Low-fat dairy products.

Protein supports muscle maintenance and overall nutritional health.

Healthy Fats

Sources include:

• Nuts.
• Seeds.
• Olive oil.
• Other unsaturated vegetable oils.

Portion control remains important because fats are calorie-dense.

18.3 Foods to Limit

Patients should reduce excessive consumption of:

• Sugar-sweetened beverages.
• Soft drinks.
• Sweetened juices.
• Cakes.
• Biscuits.
• Sweets.
• Deep-fried foods.
• Fast foods.
• Processed meats.
• Excessive refined carbohydrates.
• Highly processed snacks.

18.4 Importance of Avoiding Sugary Drinks

Sugar-sweetened beverages may contribute to excessive calorie intake and metabolic dysfunction.

Frequent consumption of these beverages is associated with increased risk of fatty liver.

Replacing them with water or unsweetened beverages is a practical dietary intervention.

18.5 Portion Control

Even healthy foods can contribute to weight gain when consumed in excessive quantities.

Patients should pay attention to:

• Portion size.
• Meal frequency.
• Total daily calorie intake.
• Cooking methods.
• Hidden sugars and fats.

18.6 Dietary Advice for Patients in South Asia

A healthy diet can be maintained using commonly available foods.

Useful choices include:

• Whole-wheat chapati in controlled portions.
• Lentils and beans.
• Fresh vegetables.
• Seasonal fruits.
• Grilled fish.
• Skinless chicken.
• Plain yogurt.
• Small portions of nuts.

Patients may reduce excessive consumption of:

• Deep-fried snacks.
• Samosas and pakoras.
• Sugary tea.
• Sweetened beverages.
• Large portions of white rice.
• Sweets and desserts.
• Foods containing excessive ghee and saturated fat.

The aim is not to eliminate traditional foods but to improve preparation methods and portion sizes.

---

19. PHYSICAL ACTIVITY AND EXERCISE

Regular physical activity is an important part of fatty liver management.

Exercise may reduce liver fat even when significant weight loss does not occur.

It also improves insulin sensitivity, cardiovascular fitness and metabolic health.

19.1 Aerobic Exercise

Examples include:

• Brisk walking.
• Cycling.
• Swimming.
• Jogging.
• Dancing.
• Recreational sports.

Adults are generally encouraged to perform more than 150 minutes per week of moderate-intensity activity or an equivalent amount of vigorous activity, according to individual ability.

19.2 Resistance Training

Resistance exercises help maintain and increase muscle mass.

Examples include:

• Weight training.
• Resistance-band exercises.
• Squats.
• Modified push-ups.
• Bodyweight exercises.

Muscle tissue plays an important role in glucose metabolism.

19.3 Reducing Sedentary Behavior

Patients should avoid prolonged sitting.

Practical recommendations include:

• Taking short walking breaks.
• Using stairs when appropriate.
• Walking after meals.
• Standing periodically during work.
• Participating in recreational physical activities.

19.4 Individualized Exercise Programs

Exercise recommendations should consider:

• Age.
• Physical fitness.
• Cardiovascular status.
• Joint problems.
• Other chronic illnesses.
• Presence of advanced cirrhosis.

Patients with significant medical conditions should discuss exercise plans with their healthcare professionals.

---

20. ALCOHOL MANAGEMENT

Alcohol consumption is an important consideration in all patients with steatotic liver disease.

Patients with MASLD should be advised that alcohol may increase liver injury, particularly when metabolic risk factors are also present.

Alcohol should be avoided in patients with advanced fibrosis and cirrhosis.

Individuals with alcohol use disorder should be offered appropriate assessment and treatment.

Management may include:

• Counseling.
• Behavioral interventions.
• Addiction treatment.
• Psychological support.
• Medically supervised withdrawal when necessary.

Patients with alcohol dependence should not attempt potentially dangerous withdrawal without medical guidance.

---

21. PHARMACOLOGICAL MANAGEMENT

There is no single medication suitable for every patient with fatty liver disease.

Treatment should be individualized according to disease stage, metabolic conditions and local regulatory approvals.

21.1 Management of Diabetes

Diabetes should be treated appropriately because poor glycemic control may worsen metabolic dysfunction.

Medications may include:

• Metformin.
• GLP-1 receptor agonists.
• SGLT2 inhibitors.
• Other glucose-lowering medications.

Metformin is useful for treating type 2 diabetes but is not an established liver-specific treatment for MASH.

21.2 GLP-1 Receptor Agonists

Examples include:

• Semaglutide.
• Liraglutide.

These medications can improve glycemic control and promote weight reduction.

Semaglutide 2.4 mg has also received approval in the United States for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis, stages F2–F3.

Its use for MASH must follow the applicable regulatory label and specialist assessment.

Important considerations include:

• Gastrointestinal adverse effects.
• Nausea.
• Vomiting.
• Diarrhea.
• Gallbladder-related complications.
• Contraindications and precautions specified in the prescribing information.

21.3 Resmetirom

Resmetirom is a thyroid hormone receptor-beta agonist that acts primarily on hepatic metabolic pathways.

It is approved in the United States for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis, corresponding to F2–F3.

It is used alongside diet and exercise.

Potential benefits include:

• Improvement in steatohepatitis.
• Reduction in liver fat.
• Improvement in fibrosis-related histological outcomes.

Important precautions include:

• Gastrointestinal adverse effects.
• Possible liver-related adverse reactions.
• Gallbladder-related adverse reactions.
• Drug interactions.
• Appropriate monitoring.

Its availability and approved indications differ between countries.

21.4 Vitamin E

Vitamin E has been investigated in selected patients with steatohepatitis.

It may be considered in carefully selected individuals after assessment of potential benefits and risks.

It is not a universal treatment for fatty liver.

Long-term high-dose supplementation may have adverse effects, so patients should not self-prescribe it.

21.5 Pioglitazone

Pioglitazone is a thiazolidinedione used in type 2 diabetes.

It improves insulin sensitivity and may improve steatohepatitis in selected patients.

However, possible adverse effects include:

• Weight gain.
• Fluid retention.
• Peripheral edema.
• Increased risk of heart failure in susceptible patients.
• Fracture risk.

Its use should be individualized.

21.6 Statins

Statins are important medications for treating dyslipidemia and reducing cardiovascular risk.

Examples include:

• Atorvastatin.
• Rosuvastatin.
• Simvastatin.

Statins are generally considered safe in patients with MASLD, including many patients with compensated chronic liver disease.

They should not be withheld simply because a patient has fatty liver.

However, they are not prescribed specifically to remove hepatic fat.

21.7 Bariatric Surgery

Bariatric surgery may be considered in selected individuals with obesity who meet established eligibility criteria.

Procedures include:

• Sleeve gastrectomy.
• Roux-en-Y gastric bypass.

These procedures may produce substantial and sustained weight loss and improve metabolic disease.

Patients with advanced liver disease require careful specialist evaluation before surgery.

---

22. MANAGEMENT ACCORDING TO DISEASE STAGE

Management varies according to the degree of steatosis, inflammation and fibrosis.

22.1 Simple Hepatic Steatosis

Main objectives include:

• Weight management.
• Healthy dietary habits.
• Regular exercise.
• Diabetes control.
• Lipid management.
• Blood pressure control.
• Alcohol assessment.

22.2 MASH Without Advanced Fibrosis

Management includes:

• Structured lifestyle intervention.
• Weight reduction when appropriate.
• Treatment of associated metabolic disorders.
• Assessment of fibrosis risk.
• Specialist-directed medication when indicated.

22.3 MASH With F2–F3 Fibrosis

These patients have clinically important fibrosis.

Management may include:

• Hepatology referral.
• Structured lifestyle intervention.
• Appropriate treatment of diabetes and obesity.
• Assessment for MASH-targeted pharmacotherapy.
• Monitoring of liver fibrosis.

Current targeted treatment options include resmetirom and semaglutide in jurisdictions where approved and when the patient meets the relevant criteria.

22.4 Cirrhosis

Patients with cirrhosis require specialized management.

Important measures include:

• Assessment for portal hypertension.
• Screening and management of esophageal varices.
• Surveillance for hepatocellular carcinoma.
• Monitoring for ascites.
• Assessment for hepatic encephalopathy.
• Nutritional support.
• Evaluation for liver transplantation when indicated.

MASH-targeted medicines approved for non-cirrhotic disease should not automatically be used as treatments for MASH-related cirrhosis.

---

23. MANAGEMENT OF CIRRHOSIS-RELATED COMPLICATIONS

23.1 Ascites Management

Treatment may include:

• Sodium restriction.
• Diuretic therapy.
• Spironolactone.
• Furosemide.
• Therapeutic paracentesis when indicated.
• Albumin administration in selected circumstances.

Patients with new or worsening ascites require medical assessment.

23.2 Variceal Bleeding

Acute variceal bleeding requires emergency treatment.

Management may involve:

• Hemodynamic stabilization.
• Blood transfusion when indicated.
• Vasoactive medications.
• Antibiotic prophylaxis.
• Urgent endoscopic treatment.
• Balloon tamponade or other rescue interventions in selected cases.
• Transjugular intrahepatic portosystemic shunt (TIPS) when indicated.

23.3 Hepatic Encephalopathy

Management may include:

• Identification of precipitating factors.
• Lactulose.
• Rifaximin in selected patients.
• Correction of dehydration and electrolyte disturbances.
• Treatment of infection or gastrointestinal bleeding.

23.4 Hepatocellular Carcinoma Surveillance

Patients with cirrhosis generally require regular surveillance for hepatocellular carcinoma.

This commonly involves liver ultrasound approximately every six months, with additional testing according to clinical circumstances and local guidelines.

---

24. FOLLOW-UP AND MONITORING

Long-term follow-up is important because fatty liver disease may progress silently.

Monitoring should assess both liver-related and metabolic health.

24.1 Body Weight and Waist Circumference

Regular measurements help assess changes in body composition and metabolic risk.

24.2 Liver Enzymes

ALT and AST may be monitored over time.

However, normal liver enzyme levels do not prove that fibrosis is absent.

24.3 Blood Glucose and HbA1c

These tests help assess glycemic control.

24.4 Lipid Profile

Monitoring cholesterol and triglycerides helps guide cardiovascular risk management.

24.5 Fibrosis Assessment

FIB-4 and appropriate imaging-based tests may be repeated according to the patient's risk profile and clinical guidance.

24.6 Monitoring of Advanced Disease

Patients with advanced fibrosis or cirrhosis may require:

• Regular specialist visits.
• Assessment for portal hypertension.
• HCC surveillance.
• Monitoring of renal function.
• Monitoring of liver synthetic function.
• Assessment of nutritional status.

The frequency of follow-up should be individualized.

---

25. PREVENTION OF FATTY LIVER DISEASE

Prevention is an essential component of reducing the global burden of fatty liver disease.

25.1 Maintain a Healthy Body Weight

Avoiding excessive weight gain reduces the risk of metabolic dysfunction.

25.2 Follow a Balanced Diet

A healthy dietary pattern should include:

• Vegetables.
• Fruits.
• Whole grains.
• Legumes.
• Healthy protein sources.
• Unsaturated fats.

25.3 Exercise Regularly

Regular physical activity improves metabolic health and reduces the risk of insulin resistance.

25.4 Control Diabetes

Good glycemic control helps reduce complications associated with metabolic disease.

25.5 Manage Cholesterol

Appropriate treatment of dyslipidemia reduces cardiovascular risk.

25.6 Control Blood Pressure

Hypertension should be treated according to established clinical recommendations.

25.7 Avoid Harmful Alcohol Consumption

Reducing alcohol exposure is particularly important in individuals with established liver disease.

25.8 Avoid Unnecessary Supplements

Some herbal preparations and dietary supplements may cause liver injury.

Patients should discuss supplements and non-prescribed medications with healthcare professionals.

---

26. FATTY LIVER IN SPECIAL POPULATIONS

26.1 Fatty Liver in Children

Fatty liver can occur in children and adolescents.

It is particularly associated with:

• Childhood obesity.
• Insulin resistance.
• Type 2 diabetes.
• Dyslipidemia.
• Sedentary behavior.

Pediatric fatty liver requires age-appropriate evaluation and management.

Children should receive family-centered nutritional counseling and physical activity support.

26.2 Fatty Liver During Pregnancy

Pregnancy may involve metabolic changes that influence liver function.

However, fatty liver detected during pregnancy requires careful evaluation because other pregnancy-related liver disorders may be responsible for abnormal liver tests.

Acute fatty liver of pregnancy is a separate, rare and potentially life-threatening condition.

It usually occurs during the third trimester and may present with:

• Nausea.
• Vomiting.
• Abdominal pain.
• Jaundice.
• Hypoglycemia.
• Coagulopathy.
• Hepatic dysfunction.

It requires emergency obstetric and medical management.

It should not be confused with ordinary chronic metabolic fatty liver disease.

26.3 Fatty Liver in Patients With Diabetes

Patients with type 2 diabetes have a particularly high risk of progressive metabolic liver disease.

They should receive appropriate assessment for fibrosis, especially when additional metabolic risk factors are present.

26.4 Fatty Liver in Lean Individuals

Not every patient with MASLD has obesity.

Some individuals with normal body weight develop hepatic steatosis due to:

• Visceral adiposity.
• Insulin resistance.
• Genetic susceptibility.
• Abnormal lipid metabolism.
• Dietary factors.
• Other metabolic abnormalities.

This is sometimes described as lean MASLD.

Normal body weight does not completely exclude metabolic fatty liver disease.

---

27. PROGNOSIS

The prognosis of fatty liver disease depends primarily on the severity of fibrosis and the presence of associated metabolic conditions.

Many individuals with simple steatosis remain stable for prolonged periods.

However, patients with MASH and significant fibrosis have a greater risk of progression.

The presence of cirrhosis substantially increases the risk of:

• Liver failure.
• Portal hypertension.
• Hepatocellular carcinoma.
• Liver-related hospitalization.
• Death.

Cardiovascular disease also represents a major contributor to adverse outcomes in patients with MASLD.

Early diagnosis and sustained management of metabolic risk factors can improve long-term outcomes.

---